Confidential Information Notice: This document and the information it contains are the exclusive property of Healthcare Regional Marketing LLC (HRM) and are proprietary and confidential. Any disclosure of such information, in whole or in part, without the express prior written consent of HRM, is strictly prohibited without written consent of HRM. Any person or entity reading this document is, by such reading, acknowledging that such person or entity is bound by this non-disclosure provision. Any unauthorized reproduction or transmission of this document is prohibited. All rights reserved. Takeda Gout Franchise Wingman Dynamic Deployment March 2015
11
Embed
Confidential Information Notice: This document and the information it contains are the exclusive property of Healthcare Regional Marketing LLC (HRM) and.
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Confidential Information Notice: This document and the information it contains are the exclusive property of Healthcare Regional Marketing LLC (HRM) and are proprietary and confidential. Any disclosure of such information, in whole or in part, without the express prior written consent of HRM, is strictly prohibited without written consent of HRM. Any person or entity reading this document is, by such reading, acknowledging that such person or entity is bound by this non-disclosure provision. Any unauthorized reproduction or transmission of this document is prohibited. All rights reserved.
Confidential Information Notice: Use or disclosure of information contained on this page is strictly prohibited and is subject to the restrictions on the title page of this document.
Why the Need for Wingman Dynamic Deployment?
• The field is taxed with the launch of a new drug
• Optimal details will be impacted and there is the opportunity for the Brand team to partner with Sales in order to help maintain optimal touch points with key HCPs
• Create additional opportunities for Reps to engage HCP customers
• Extend the Rep relationship during this hectic time
• Create integrated approach in partnership with Brand team
2
3Confidential Information Notice: Use or disclosure of information contained on this page is strictly prohibited and is subject to the restrictions on the title page of this document.
Regional Gout Multi-Channel Program
• Gout Wingman Dynamic Deployment
Multi-Channel Marketing
The Solution: Wingman Dynamic Deployment Campaign
• Supports detailing efforts by creating thousands of additional touch points for
HCPs with sub-optimal calls
Benefits to Representatives
• Automatically identifies HCPs in need of additional touch points and automatically
sends them communications
• Supplements Rep efforts and extends the Rep relationship with HCP as
communications are sent on behalf of the primary Rep – complete with their
signatures
Wingman – It’s Got Your Back!
The Problem:
• Today’s environment of reductions in the number of Reps, compounded
by Reps carrying multiple products in their bags, creates a challenge in
attaining detail frequency goals
• HCP access presents an additional challenge for Reps achieving detail
frequency goals
4Confidential Information Notice: Use or disclosure of information contained on this page is strictly prohibited and is subject to the restrictions on the title page of this document.
The Solution: Wingman Dynamic Deployment System Based on Frequency
12
12
6
0
6
0
= Field Force Detail
= MCM
Current Touch Points
New Touch Points
• Frequency + Multi-Channel = additional lift
• MCM dynamic deployment system designed to supplement field frequency and
optimize marketing budgets
• Applied intelligent business rules to pinpoint critical targets and adjust based on
Field Force activity
Confidential Information Notice: Use or disclosure of information contained on this page is strictly prohibited and is subject to the restrictions on the title page of this document. 5
Wingman Dynamic Deployment Process
Step 2Create targeting business rules for deployment
Step 5 Begin mailing the letters to targets identified on target list
Step 3 Identify the Wingman DD target list
Step 4Kickoff program with the field force
Step 6 HRM to pull data monthly in order to continue to update and evolve the target lists for deployment and field force communications
Step 1 Create six clinical Gout focused direct mail letters (3 ULORIC; 3 COLCRYS) based on previously approved brand materials
6Confidential Information Notice: Use or disclosure of information contained on this page is strictly prohibited and is subject to the restrictions on the title page of this document.
7Confidential Information Notice: Use or disclosure of information contained on this page is strictly prohibited and is subject to the restrictions on the title page of this document.
• Both Brands recently dropped thousands of HCPs from their target lists
• Target both ULORIC® and COLCRYS® HCPs Deciles 5-10
– Called on (Contrave Targets) + Non-called on (recently dropped)– Include Rep name and signature on letters
• Establish a unique set of business rules that will identify HCPs that are sub-optimally detailed and send them Brand letters
– List/targets can be adjusted throughout the program
• This allows the Brand to extend reach and frequency towards Deciles that have ‘distracted’ Reps and/or Reps that no longer service the footprint
– Brand will measure TRx for this group in order to track ROI
8Confidential Information Notice: Use or disclosure of information contained on this page is strictly prohibited and is subject to the restrictions on the title page of this document.
Wingman Dynamic Deployment: Business Rules and Deciling
• Business Rules– Filtered for targets only– Removed all on AMA no contact list– Removed all on Takeda no contact list– Treated Uloric and Colcrys separately for 2 letter max, some docs will recieve
4 letters• Deciles 5-6 have 4+ differential• Deciles 7-8 have 2-3 and 3+ differential • Deciles 9-10 have 1-2+ differential
• Number of Letters to be deployed: – Colcrys letters per month = ~7,188– Uloric letters per month = ~21,084
– Total letters targeting HCPs per month = ~28,000
9Confidential Information Notice: Use or disclosure of information contained on this page is strictly prohibited and is subject to the restrictions on the title page of this document.
Wingman Dynamic Deployment:Printing & Deployment Vendor Role
• Vendor to print and distribute monthly mailings, targeting ~28,000 HCPs dependent upon monthly target list
• HRM will work with Gout Brand team to pull data each month, adjust business rules as necessary and create target list
• Mailings include the following:– Branded Letter – Brand’s PI– Envelope
Wingman Communication Plan to Ensure Field is Informed and Integrated
• Opportunity
– Educate Field Force Partners on Wingman Campaign in order
to allow them to build on those additional communications and
pull through additional engagement opportunities
– Create an innovative communication platform to highlight the
program and educate and gain buy-in from all Field Force
stakeholders
• Campaign
– Develop Rep Awareness pull-through campaign to include:
• Coordinating with brand team and outside vendor that
manages i-engage and i-market to ensure HCPs are
flagged as targeted
• Create communications that include program details and
updates are included periodically in the weekly sales
newsletter (six communications in total)
10Confidential Information Notice: Use or disclosure of information contained on this page is strictly prohibited and is subject to the restrictions on the title page of this document.
11Confidential Information Notice: Use or disclosure of information contained on this page is strictly prohibited and is subject to the restrictions on the title page of this document.
Performance Metrics: Wingman Dynamic Deployment
Wingman Dynamic Deployment Campaign: 4.5-5X ROI
• Quantitative Methodology
– Market-Level (ROI)
• Assign markets as control groups
• Measure pre- and post- performance in targeted markets vs. control markets
• Qualitative Survey Results:– Representatives have shared positive reaction from HCPs as well as an increase in HCP